HIM
FOLD

Hillsdale Investment Management’s Amicus Therapeutics FOLD Stock Holding History

Hillsdale Investment Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-365,800
Closed -$3.91M – 615
2024
Q3 		$3.91M Buy
365,800
+94,000
+35% +$1.02M 0.3% 128
2024
Q2 		$2.7M Sell
271,800
-48,000
-15% -$493K 0.21% 171
2024
Q1 		$3.77M Buy
319,800
+25,500
+9% +$326K 0.3% 138
2023
Q4 		$4.18M Buy
294,300
+23,640
+9% +$268K 0.34% 98
2023
Q3 		$3.29M Buy
270,660
+180
+0.1% +$2.32K 0.3% 131
2023
Q2 		$3.4M Sell
270,480
-130,320
-33% -$1.55M 0.31% 136
2023
Q1 		$4.44M Buy
400,800
+700
+0.2% +$8.63K 0.38% 93
2022
Q4 		$4.89M Buy
+400,100
New +$4.5M 0.41% 73

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hillsdale Investment Management's FOLD Position: Q4 2024 in Review

Hillsdale Investment Management sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 365,800 shares — an estimated $3.91M sold.

Hillsdale Investment Management first reported a position in FOLD in Q4 2022 and held it in 8 quarters. The position peaked at $4.89M in Q4 2022. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • Hillsdale Investment Management reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 365,800 Amicus Therapeutics shares in Q4 2024, an estimated $3.91M.
  • Hillsdale Investment Management first reported a position in Amicus Therapeutics in Q4 2022 and held it in 8 quarters.
  • Hillsdale Investment Management's Amicus Therapeutics position peaked at $4.89M in Q4 2022.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Hillsdale Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.